Skip to content
  • News
  • Insights
  • Interviews
  • Reports
  • Newsletter
Main Menu
  • News
  • Insights
  • Interviews
  • Reports
  • Newsletter

About Me

Nick Mars - Lorem ipsum dolor sit amet, consectetur adipisicing elit. Minima incidunt voluptates nemo, dolor optio quia architecto quis delectus perspiciatis. Nobis atque id hic neque possimus voluptatum voluptatibus tenetur, perspiciatis consequuntur.

Social Icons

Facebook1,750FansLikeX (Twitter)759FollowersFollowInstagram2,500FollowersFollowPinterest1,365FollowersPinYoutube2,700SubscribersSubscribeTiktok2,900FollowersFollowTelegram2,000MembersJoinSoundcloud1,963FollowersFollowVimeo1,254FollowersFollowDribbble3,520FollowersFollow
  • Support
    • Documentation
    • Documentation
    • Video Tutorials
    • Video Tutorials
    • Support Forums
    • Support
  • Support
  • About Theme
  • About theme
  • Visit Us
  • Visit Us
Wednesday, June 24, 2026
Home / Ophthalmic Suspension

Browsing Tag: Ophthalmic Suspension

  • News
  • Regulatory

Apotex Expands Ophthalmology Portfolio with Health Canada Approval of CLOBIVIS 

Takeaways:   CLOBIVIS modestly strengthens Apotex’s position in Canada’s post‑cataract segment and helps it move up the value chain in eye care beyond pure generics.  In marke...

Arisa Smith
March 25, 2026
Read More

Social Icons

Facebook1,000FansLikeX (Twitter)1,000FollowersFollowInstagram1,000FollowersFollowPinterest1,000FollowersPinYoutube1,000SubscribersSubscribeTiktok1,000FollowersFollowTelegram1,000MembersJoinSoundcloud1,000FollowersFollowVimeo1,000FollowersFollowDribbble1,000FollowersFollow

Featured Posts

1
AbbVie’s Boey Approved in Canada for Glabellar Lines 
June 24, 2026
2
Roche’s Itovebi Moves Closer to Public Access in Canada 
June 24, 2026
3
Takeda’s Zasocitinib Beats Deucravacitinib in Psoriasis Phase 3 Trial 
June 24, 2026
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Minima incidunt voluptates nemo, dolor optio quia architecto quis delectus perspiciatis.

Nobis atque id hic neque possimus voluptatum voluptatibus tenetur, perspiciatis consequuntur.

Email: sample@gmail.com
Call Us: +987 95 95 64 82

Category List

  • Commercial(11)
  • Companies(13)
  • Deals(5)
  • Editor's Pick(5)
  • Latest Updates(1)
  • Manufacturing(6)
  • Must Read(4)
  • News(66)
  • Opinions(30)
  • Public Health(10)
  • R&D(12)
  • Regulatory(38)
  • Technology(8)

Featured Posts

1
AbbVie’s Boey Approved in Canada for Glabellar Lines 
June 24, 2026
2
Roche’s Itovebi Moves Closer to Public Access in Canada 
June 24, 2026
3
Takeda’s Zasocitinib Beats Deucravacitinib in Psoriasis Phase 3 Trial 
June 24, 2026
Copyright © 2026 | Powered by News Magazine X